摘要:
Silicone polyoxamide and silicone polyoxamide-hydrazide copolymers comprise at least two repeating units of formula I In this formula, each R1 is independently an alkyl, haloalkyl, aralkyl, alkenyl, aryl, or aryl substituted with an alkyl, alkoxy, or halo; each Y is independently an alkylene, aralkylene, or a combination thereof; each G is independently a bond or a divalent residue equal to a diamine of formula R3HN-G-NHR3 minus the two —NHR3 groups; each R3 is independently hydrogen or alkyl or R3 taken together with G and with the nitrogen to which they are both attached form a heterocyclic group; each n is independently an integer of 0 to 1500; each p is independently an integer of 1 to 10, and the average of p is 1.2 or greater; and each q is independently an integer of 1 or greater, and every q is not the same integer.
摘要:
The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.
摘要:
The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.
摘要:
A one-pot process for the preparation of alkoxyamines conforming to formulae (I) or (II), preferably (I) 1 is disclosed. The process entails (1) reacting of an oxidizing agent (A) with a sterically hindered secondary amine of the general formula (III), 2 in a water-containing medium to form a reaction product and an aqueous phase, (2) removing of the aqueous phase, and (3) (adding to the reaction product a free-radical initiator (B) under conditions that promote the decomposition of the initiator to generate free radicals. Also disclosed is a process for polymerizing monomers, the process using the alkoxyamine prepared by the inventive process.
摘要:
Ophthalmic pharmaceutical compositions containing a pharmaceutically acceptable ophthalmic carrier and an inflammation-treating amount of a nitrone compound are disclosed. Also disclosed are methods for treating ocular inflammation conditions, such as uveitis, using pharmaceutical compositions.
摘要:
A process for producing tertiary amine oxide having two methyl or ethyl groups and one long chain primary aliphatic group in a stable, solid form is described. Aqueous 65-90% hydrogen peroxide and tertiary amine having two methyl or ethyl groups and one primary aliphatic hydrocarbyl group of 8-24 carbon atoms are mixed in proportions of ca. 1.1-1.3 moles of hydrogen peroxide per mole of tertiary amine in the presence of carbon dioxide and in the absence of organic solvent. When the conversion of the tertiary amine to tertiary amine oxide in the reaction mass has reached ca. 60-90%, the reaction mass is transferred to a separate vessel and the reaction mass is then allowed to solidify at a temperature of ca. 20-60.degree. C. The process makes possible the production of highly pure solid product without formation of any appreciable amounts of undesirable by-products. Also, the process is environmentally friendly, and the problems and expense associated with product workup, purification, crystallization, and waste product disposal are largely, if not entirely, avoided. Moreover, the solid storage stable products can be stored and shipped at significantly reduced costs as compared to liquid solutions. The products are useful in the manufacture of household and commercial laundry detergent formulations furnished in the form of powders or flakes.
摘要:
The invention is the use of nitronyl substituted hindered phenols as antioxidants in therapeutic applications. In the preferred embodiment the compositions have the general formula: ##STR1## Wherein R1 is hydrogen, an alkyl or an aryl and R2 is an alkyl or an aryl; R.sub.3 is an alkyl; and R.sub.4 is an alkyl. Further, the invention relates to novel compositions useful as antioxidants. The novel compounds include: 2,6-di-tert-butyl-4-(N-tert-octyl)nitronyl phenol (DBONP); 2,6-dimethyl-4-(N-tert-octyl)nitronyl phenol (DMONP); N-tert-octyl-C-phenyl nitrone (OPN).
摘要:
Spin trapping compositions in general have now been discovered to be effective in treating a variety of disorders, including disorders such as those arising from ischemia, infection, inflammation, exposure to radiation or cytotoxic compounds, not just of the central and peripheral nervous systems but of peripheral organ disease having a wide variety of etiologies. In the preferred embodiment, the compositions for treating tissue damage from ischemia contain PBN, or active derivatives thereof, in a suitable pharmaceutical carrier for intravenous, oral, topical, or nasal/pulmonary administration. Other preferred spin-trapping agents include 5,5-dimethyl pyrroline N-oxide, (DMPO), .alpha.-(4-pyridyl-1-oxide)-N-tert-butylnitrone, (POBN), and (TEMPO) spin-trapping derivatives thereof. Examples of derivatives of PBN include halogenated derivatives, bifunctional derivatives, conjugates with drugs or targeting molecules, dimers and cyclodextran polymers of PBN. Many different disorders can be treated using these compounds, including diseases or disorders of the central and peripheral nervous systems, and disorders arising from ischemia, infection, inflammation, oxidation from exposure to radiation or cytotoxic compounds, as well as due to naturally occurring processes such as aging.
摘要:
Thermoplastic resin composition are provided that comprise a thermoplastic resin or mixture thereof, a stabilizing amount of a stabilizer or mixture of stabilizers selected from the group consisting of the phenolic antioxidants, the 3-arylbenzofuranones, the hindered amine stabilizers, the ultraviolet light absorbers, the organic phosphorus compounds, the alkaline metal salts of fatty acids, the hydroxylamines, and the thiosynergists, and a stabilizing amount of a tertiary amine oxide. The compositions have improved stability against discoloration upon exposure to heating or to the combustion products of natural gas by the concomitant presence of an effective amount of a tertiary amine oxide.
摘要:
2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.